Company Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A.
for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.
TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
| Country | United States |
| IPO Date | Dec 14, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 264 |
| CEO | Michael S. Weiss Esq. |
Contact Details
Address: 2 Gansevoort Street, 9th Floor New York, New York 10014 United States | |
| Phone | (212) 554-4484 |
| Website | tgtherapeutics.com |
Stock Details
| Ticker Symbol | TGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001001316 |
| CUSIP Number | 88322Q108 |
| ISIN Number | US88322Q1085 |
| Employer ID | 36-3898269 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael S. Weiss Esq. | Chairman, Chief Executive Officer and President |
| Sean A. Power CPA | Chief Financial Officer, Corporate Secretary and Treasurer |
| Jenna Bosco | Senior Vice President of Corporate Communications |
| Adam Waldman | Chief Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2024 | 144 | Filing |
| Mar 12, 2024 | 144 | Filing |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2024 | 8-K | Current Report |